Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) has completed an upsized public offering, raising $201 million. The offering was supported by investment banks Jefferies and Goldman Sachs & Co. LLC. Legal counsel for Corvus was provided by Latham & Watkins LLP, while Paul Hastings LLP advised the underwriters.
The funds raised through this offering are expected to support Corvus Pharmaceuticals’ ongoing research and development activities as well as general corporate purposes.
**Why this matters**
This capital infusion strengthens Corvus Pharmaceuticals’ financial position, enabling continued advancement of its drug development programs. It also reflects investor confidence in the company’s pipeline and strategic direction.
Source: NewsData